National Laser Institute
MARCH 28, 2025
In today’s changing world of medical aesthetic treatments, non-invasive cosmetic injections, such as Botox, have gained tremendous popularity. With this. Read more » The post Botox Courses Near You: Understanding the Process of Botox Treatments appeared first on National Laser Institute.
Dermatology Times
MARCH 28, 2025
An expert discusses the detection of circulating tumor DNA (ctDNA) prior to surgery, noting higher detection rates in stage III patients compared with stage IIB/C patients, and its significant association with a greater number of involved lymph nodes, extracapsular extension, and clinically evident disease, while also highlighting that all 6 patients with ctDNA detected during the surveillance period developed recurrent melanoma.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
National Laser Institute
MARCH 28, 2025
In the lively beauty industry, medical aesthetics is headed at the forefront of its growth. With this considered, as non-surgical. Read more » The post A Career as a Medical Aesthetician: Opportunities and Specialties appeared first on National Laser Institute.
US Dermatologt Partners
MARCH 28, 2025
We combine the personal care found in private dermatology practices with the benefits of a network of physicians working together.
National Laser Institute
MARCH 28, 2025
In today’s medical aesthetic landscape, the rise of non-invasive cosmetic treatments, such as dermal fillers and Botox, have provided a. Read more » The post Cosmetic Injector Training Near You: From Consultation to Follow-Up appeared first on National Laser Institute.
The Dermatology Digest
MARCH 28, 2025
Christie Brinkleywill host The Skin Cancer Foundations Champions for Change Gala, which is scheduled for Wednesday, May 14, 2025, at the Ziegfeld Ballroomin New York City. Ms. Brinkley was inspired to host the event after her own recent skin cancer diagnosis and treatment. La Roche-Posay will receive the Foundations Champions for Change Award at the event, in recognition of its long-standing partnership and commitment to the Foundations mission.
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
The Dermatology Digest
MARCH 28, 2025
Quoin Pharmaceuticals has filed a U.S. patent application for novel topical formulations to treat several skin diseases, including Netherton Syndrome (NS). Quoins lead product, QRX003, is currently being tested in four Netherton Syndrome clinical trials. Three of these trials are being conducted under Quoins open Investigational New Drug (IND) application with the US Food and Drug Administration (FDA).
National Laser Institute
MARCH 28, 2025
In the wonderful world of medical aesthetics, it is important to stay ahead of the curve and hone your skillset. Read more » The post Neurotoxin Training in Phoenix: Seize the Day! appeared first on National Laser Institute.
Dermatology Times
MARCH 28, 2025
With an increasing demand for laser procedures, AI-based skin assessments may help ensure safer and more effective treatments.
Beauty Launchpad
MARCH 28, 2025
Beauty Launchpad was in attendance at Questex's International Beauty Show (IBS NY) held at the Javits Center. Here, we recap what you missed if you weren't able to attend.
National Laser Institute
MARCH 28, 2025
In the rapidly expanding field of medical aesthetics, Botox has emerged as a cornerstone treatment, renowned for its remarkable ability. Read more » The post Benefits of Botox Classes: Kickstart Your Aesthetic Career appeared first on National Laser Institute.
Beauty Launchpad
MARCH 28, 2025
The 2025 Hairbrained Awards shined a spotlight on the most talented and innovative artists in the professional hair industry. Read on to see the full list of winners.
Salon Today
MARCH 28, 2025
The new Oribe Serene Scalp Densifying Collection offers stylists and their clients an effective solution for thinning hair concerns.
Dermatology Times
MARCH 28, 2025
Explore the top headlines of the week including insights on recalls, expert pearls, and more.
The Dermatology Digest
MARCH 28, 2025
Mona Shahriari, MD, an Assistant Clinical Professor of Dermatology at Yale University School of Medicine in New Haven, CT, and the Associate Director of Clinical Trials at Central Connecticut Dermatology (CCD) Research, shares her updated monitoring protocols for patients on biologics, Janus kinase (JAK), and Tyrosine Kinase 2 (TYK2) inhibitors. Dr.
Dermatology Times
MARCH 28, 2025
Dermatology Times is looking back on the top stories in dermatology from the month of March.
Dermatology Times
MARCH 28, 2025
Catch up on dermatology news, highlights, and insights from the past 24 hours.
Dermatology Times
MARCH 28, 2025
Learn more about the in-depth topics covered in the March 2025 print issue of Dermatology Times.
Dermatology Times
MARCH 28, 2025
Lisa Swanson, MD, FAAD, discusses how factors such as the safety profile, efficacy, age-appropriate dosing, and potential long-term effects of ruxolitinib cream would be crucial in determining its place in treatment for young children.
Dermatology Times
MARCH 28, 2025
Two-sample Mendelian randomization analysis explored lifestyle factors such as sleep, smoking, alcohol consumption, and sedentary behavior.
Dermatology Times
MARCH 28, 2025
Lisa Swanson, MD, FAAD, discusses how to balance the need for effective control of Alzheimer's disease symptoms with concerns about long-term safety, particularly when introducing new therapies.
Dermatology Times
MARCH 28, 2025
Panelists discuss how to implement and maintain appropriate laboratory monitoring protocols when prescribing oral JAK inhibitors, ensuring patient safety through regular assessment of key clinical parameters.
Dermatology Times
MARCH 28, 2025
Panelists discuss how unique characteristics of different JAK inhibitors, including selectivity profiles, administration routes, and clinical efficacy data, inform treatment selection in real-world practice.
Dermatology Times
MARCH 28, 2025
An expert discusses initial thoughts on the case, including the risk category the patient would fall into based on the characteristics of their lesion, outlines the treatment guidelines for melanoma based on their risk, and suggests the frequency of surveillance visits solely based on their traditional risk classification.
Dermatology Times
MARCH 28, 2025
Lisa Swanson, MD, FAAD, discusses how current treatment options for this age group fall short in terms of disease control, safety, and ease of use, while highlighting emerging options that promise better efficacy, fewer side effects, and greater convenience.
Dermatology Times
MARCH 28, 2025
Lisa Swanson, MD, FAAD, discusses how caregivers play a crucial role in ensuring successful long-term AD management by providing daily support, monitoring treatment adherence, and offering emotional support, while dermatologists can better support them through education, clear communication, and collaborative care strategies.
Dermatology Times
MARCH 28, 2025
Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.
Dermatology Times
MARCH 28, 2025
Panelists discuss how IL-17 inhibitors are biologics that target the inflammatory cytokine IL-17 pathway. They demonstrate rapid onset of action, with measurable improvement in most patients within 2 to 4 weeks and peak efficacy by 12 to 16 weeks. They achieve high rates of skin clearance in psoriasis patients and maintain efficacy with long-term use.
Dermatology Times
MARCH 28, 2025
Panelists discuss how inhibition of IL-17 in psoriasis treatment significantly improves quality of life by reducing inflammation, skin lesions, itching, and pain. Patients report better psychological well-being, increased social confidence, and improved daily functioning as inflammatory pathways are interrupted.
Dermatology Times
MARCH 28, 2025
The therapy, which combines clindamycin phosphate, adapalene, and benzoyl peroxide, was effective for Hispanic patients with moderate to severe lesions.
Dermatology Times
MARCH 28, 2025
Patients with CHE saw higher treatment success and a favorable safety profile with delgocitinib 20-30 mg/g.
Expert insights. Personalized for you.
52 
Let's personalize your content